China forecasted as the fastest growing biologics market over the next decade with Chinese NCEs within 5 years
![](/46/pdcnewsitem/04/15/43/CPhI%20China.jpg)
International-domestic pharma partnerships to drive next wave of growth, alongside emerging Chinese multinational CMOs.
CPHI Worldwide, organised by UBM EMEA, announces the findings of the latest CPHI Pharma Insights report on the Chinese pharma economy. This comprehensive report was released at CPHI China 2016 and unequivocally shows the confidence of international companies in the expanding Chinese market.
In fact, of the international companies surveyed, a remarkable 85% believe that China is set to have the fastest growing biologics sector over the next decade, whilst 65% predict patented new chemical entities (NCEs) will be discovered and developed within the country in as little as 5 years’ time. The driving force behind these findings is the growing biotechnology and R&D industry, which is heavily supported by the Chinese Government.
As a result, Big Pharma and generic manufacturers are increasingly attempting to gain access to the Chinese market, with 74% of international companies looking to ‘increase or initiate partnership with local companies’. This remains a key trend as both international and Chinese companies are seeing natural synergies — Chinese companies benefit from increasing their knowledge of advanced technologies and international companies benefit from market access with a partner familiar with its complexities. These arrangements and strategic alliances will proliferate over the next few years, as 90% of domestic companies are also searching for international partners, and their primary goal is to increase the ‘company’s knowledge and development base’.
Interestingly, over half of the domestic respondents believe ‘the Chinese manufacturing sector will advance their manufacturing capabilities in complex formulations and biologics to levels comparable to those in the West within the next 3–5 years’. Emphasising the shift towards developing higher manufacturing and regulatory standards, over 60% of companies surveyed are already implementing GMP standards, 40% Quality by Design, 40% continuous improvement, and nearly 20% either six-sigma or OPEX.
International companies also share a renewed confidence in the improvement of standards within the Chinese market, with over 50% stating that they believe ‘commercial manufacturing can be competently outsourced within China’. Moreover, nearly 30% believe both ‘CMO activity’ and ‘clinical drug supply and formulation services’ can be competently undertaken by Chinese companies — most remarkably, 27% believe ‘US and European drug supply’ can also be completed by manufacturers within the country.
The report concludes that the chief driving force behind rising standards within the Chinese market – and therefore its export potential – has paradoxically been an increased awareness amongst domestic consumers and the desire for more tightly regulated, higher-quality drugs.
Chinese companies are increasingly investing for the future, with 21% investing in cold chain storage technology, 16% in ADC development, 43% commercial and scale-up facilities and perhaps most interestingly, 27% in continuous processing. Continuous processing remains at the cutting edge of the industry and is predicted to revolutionise pharma manufacturing over the next decade. However, its initial set-up costs and new learning’s are high, implying a significant change in approach from Chinese companies.
Two major challenges were identified as potential drag factors. Firstly, finished drug supply of solid dose forms is not showing the accelerated pace of development that the biologics sector is experiencing, and the report postulates that ‘too much ground has been ceded to Western and Indian manufacturers’ who lead this sector internationally. Secondly, as China’s overall pharma economy expands, the CFDA is experiencing greater backlogs and regulatory bottlenecks. The domestic industry strongly supports the implementation of a US-style GDUFA system to alleviate these pressures and an overwhelming 94% stating that the ‘CFDA must grow rapidly to a comparable size to the US FDA if it is to properly regulate its industry’.
The reports ends by stating that in 5 years’ time, the Chinese pharma market will look very different, with generics and APIs still being exported in huge numbers, but alongside this, there will also be a well-established biologics and research industry, with multinational CMOs. In fact, it is likely that in as little as 5–10 years’ time, there will be Chinese patented NCEs — which have been researched, clinical trial manufactured, and distributed by Chinese companies — specifically developed for local patient cohorts.
Another area international pharma is increasingly looking to invest in, is traditional Chinese medicines (TCMs), with 79% of companies seeking to enter this market in the next few years. The consensus amongst international pharma and generic companies is that “if you can’t beat them, join them”, as clearly, there remains an overwhelming growth opportunity to be harnessed.
Overall, confidence in the short-term growth remains extremely high, with 25% of domestic companies believing China will soon be the world’s top biopharma innovator. Emphasising this shift, 41% believe future biologic sales will be predominantly led by international exports.
The majority of foreign companies are forecasting explosive growth in China as the country’s healthcare system evolves over the next 5 years. Not only do 60% of foreign organisations, who are already present in the market, project their sales will grow by more than 25%, 15% are even predicting a staggering growth of 200% or greater over the next 5 years. Similarly, over 70% of Chinese firms are either ‘confident’ or ‘extremely confident’ in the sustained buoyancy of the Chinese market and 65% of Chinese firms expect growth of around 20% in the next year alone. A further 26% anticipate growth at 20-40%, with 8% expecting to double in size. This suggests that despite a recent, relative slow-down in the overall Chinese economy, the pharma sector remains extremely buoyant.
“This report mirrors our experiences on-the-ground during CPHI China 2016 where there was a clear confidence in future prospects from both international and domestic companies. What is noticeable is a renewed commitment to investing for longer-term growth, with partnerships and manufacturing deals becoming increasingly ambitious. The API and generic market will remain extremely strong and biologics investment and production will proliferate. Our research suggested that within 5 years China is going to be challenging on a number of fronts – with international CMOs and perhaps even locally researched and developed NCEs. Already this year, we have seen a considerable expansion of the event to 35,000 attendees, a 5000 increase, and we are looking to grow alongside the Chinese pharma economy,” said Chris Kilbee, Group Director Pharma, UBM EMEA.
Related News
-
News CPHI North America 2024 – From the Floor
Welcome to Philly! CPHI North America once again graces the Philadelphia Convention Center, 7–9 May 2024. -
News Women in Pharma: Diversi‘tea’ at CPHI North America
CPHI North America will unite the pharmaceutical supply chain in Philadelphia from May 7–9, 2024 for 3 days of innovation and connections. As part of the content Agenda, our Diversity Track will bring the industry together to discuss the imperati... -
News More to celebrate at the CPHI Milan Pharma Awards 2024
The CPHI Milan Pharma Awards, which are now open for nominations until 18 May 2024, celebrate the innovators making a difference. This year, two new categories have been added to further honour the contributions of a diverse range of pharma professiona... -
News On Track at CPHI NA 2024: Sustainable Futures with Thermo Fisher Scientific
On the 7-9 May 2024 in Philadelphia, CPHI NA will be presenting an unmissable agenda, filled with content across 4 main tracks. In the following interview the Sustainable Futures Track sponsor, Thermo Fisher Scientific gives an overview of what to expe... -
News LEAP-ing into the future of pharma – the CPHI Middle East Vision
On March 6, 2024, the CPHI team hosted the Future of Pharma Forum at LEAP 2024, Saudi Arabia’s premier destination for tech leaders and innovators to meet and collaborate. -
News CPHI Middle East 2024 – What do we have to look forward to?
We’re bringing CPHI to the Middle East in December 2024. CPHI brings together the pharma community from all over the world, creating a platform for education, collaboration, and progress. -
News CPHI Pharma Awards 2023 – Packaging & Machinery Winner: Gasporox
After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October 2023. In this series of interviews, we speak to the people and teams behind the award-winning projects, concepts, and techno... -
News Unpacking what we learnt: Key Pharmapack takeaways with L.E.K. Consulting
After another successful Pharmapack show, we sat down with Karin von Kienlin, Senior Partner at L.E.K. Consulting, to discuss the biggest takeaways and surprises from 2 days of intense discussion and collaboration.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance